LJLidong Jiao

Lidong Jiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lidong Jiao has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Chunqiu Fan

    Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China

    1 shared publication
  • Hong Zhao

    Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China

    1 shared publication
  • Huixin Shen

    Neurology Department, Xuanwu Hospital of Capital Medical University, Beijing, People’s Republic of China

    1 shared publication
  • Jian Chen

    Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China

    1 shared publication
  • Jiangang Duan

    Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China

    1 shared publication
  • Mangmang Shi

    School of Physics, MOE Key Laboratory for Non-Equilibrium Synthesis and Modulation of Condensed Matter, Key Laboratory of Shaanxi for Advanced Functional Materials and Mesoscopic Physics, State Key Laboratory for Mechanical Behavior of Materials, Xi'an Jiaotong University, Xi'an, 710049, China

    1 shared publication

Latest Publications

  • Outstanding electrochemical performance of nickel-cobalt phosphate sheets with abundant mesopores for use in aqueous asymmetric supercapacitors and Ni–Zn batteries

    by Min Li, Mingshu Zhao, Stefanos Mourdikoudis, Qingyang Zheng, Lidong Jiao, Zhou Su, Mangmang Shi, Qiuwen Wang, Yiming Wu, Sen Yang


  • Open Access

    Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia

    by Lidong Jiao, Xiaoqin Huang, Chunqiu Fan, Hong Zhao, Zhen Li, Huixin Shen, Jian Chen, Jiangang Duan

    Background and Objective: Essential thrombocythemia (ET) is a rare cause of cerebral venous sinus thrombosis (CVST). Analysis of the risk factors and treatment therapies of CVST in ET has yielded controversial findings. Subjects and Methods: We retrospectively investigated the clinical characteristics of CVST events in ET and compared baseline characteristics, causative factors, hematological effects, and treatments between ET patients with and without CVST. Results: Overall, 91 of 115 patients who met the ET diagnosis were included in this study. Among them, 23 (25.27%) patients met the diagnostic criteria of ET with CVST for inclusion, 14 (60.87%) of whom were females, with a median age of 34 (range 25– 50). CVST diagnosis was made concomitantly to ET in 19 patients (82.61%). The most common symptom and sites of thrombosis of CVST was an acute or subacute headache and sigmoid sinuses, respectively. Compared with ET patients without CVST, ET patients with CVST were significantly younger (37.65± 14.45 vs 60.93± 13.46, P< 0.001) and had lower prevalence of hypertension (4.34 vs 32.35%, P=0.003) and coronary artery disease (0 vs 14.71%, P = 0.045). Patients with CVST presented with significant lower platelet count (510.39± 176.71 vs 750.82± 249.10, P< 0.001) and higher score of IPSET-thrombosis (P=0.017). Multivariate logistic regression analysis indicated that age (P=0.002, OR 1.096, 95% CI 1.035– 1.161), at least one CVRF (P = 0.024, OR 0.037, 95% CI 0.002– 0.649), platelet count (P=0.045, OR 0.994, 95% CI 0.989– 1.001), and lower percentage of antiplatelet therapy (P=0.035, OR 0.307, 95% CI 0.001-1.280) significantly contributed to the risk of CVST in ET. Conclusion: Most patients (95.65%) had a favorable outcome without recurrence after standard anticoagulant and cytoreductive treatment at last follow-up. These findings indicate that CVST may be the initial presentation of ET, with its detection crucial for early diagnosis and appropriate management. Anticoagulant and cytoreductive therapies should be recommended for preventing ET-related CVST with JAK2 V617F mutation.